NCT01225172 - Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Breast Cancer

Interventions

DRUG

BMS-754807

Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity

DRUG

letrozole

Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity

Trial Locations (21)

20902

Oncology Care Associates, P.A., Wheaton

21231

Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore

22908

University Of Virginia Health System, Charlottesville

27599

Unv. Of Nc At Chapel Hill, Chapel Hill

27710

Duke University Medical Center-Dept Of Medicine, Durham

28204

Presbyterian Hospital Cancer Research, Charlotte

32224

Mayo Clinic, Jacksonville

35294

Univ Of Al At Birmingham, Birmingham

46526

Indiana University Health Goshen Center For Cancer Care, Goshen

53792

University Of Wisconsin, Madison

55455

Masonic Cancer Ctr, University Of Minnesota, Minneapolis

55905

Mayo Clinic, Rochester

60637

University Of Chicago Medical Center, Chicago

61615

Illinois Cancercare, Pc, Peoria

77030

Ut Md Anderson Can Ctr., Houston

85259

Mayo Clinic Arizona, Scottsdale

92123

Sharp Clinical Oncology Research, San Diego

21231-1000

Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore

27599-7305

Unv. Of Nc At Chapel Hill, Chapel Hill

77030-4009

Ut Md Anderson Can Ctr., Houston

53792-6164

University Of Wisconsin, Madison